Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
about
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingTgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growthCanonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent mannerAdvancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.TIEG1 modulates β-catenin sub-cellular localization and enhances Wnt signaling in bone.Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseOsteoblastogenesis and tumor growth in myeloma.Update in new anabolic therapies for osteoporosisAdvances in the understanding of myeloma bone disease and tumour growth.Lithium suppresses astrogliogenesis by neural stem and progenitor cells by inhibiting STAT3 pathway independently of glycogen synthase kinase 3 beta.Novel therapeutic targets in myeloma bone disease.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsDickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic interventionTranscriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myelomaDifferential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma.Growth factor control of bone mass.Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.Metastasis and bone loss: advancing treatment and prevention.Bone cement augmentation procedures for spinal pathologic fractures by multiple myelomaCharacterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneHost-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.Bone anabolic agents for the treatment of multiple myeloma.Targeting bone as a therapy for myeloma.Osteoblastic and vascular endothelial niches, their control on normal hematopoietic stem cells, and their consequences on the development of leukemiaNew treatment modalities in osteoporosis.Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft modelGlycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.Preclinical animal models of multiple myelomaWnt signaling in bone formation and its therapeutic potential for bone diseases.Role of decorin in the antimyeloma effects of osteoblasts.TCF3, a novel positive regulator of osteogenesis, plays a crucial role in miR-17 modulating the diverse effect of canonical Wnt signaling in different microenvironments.Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.Cellular mechanisms of multiple myeloma bone diseaseGenetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myelomaThe proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
P2860
Q28082335-C5D79D9D-733F-4DC7-9A20-1F76FB602573Q28473419-C7A1FE56-8CAF-4850-82A5-AA3EBCB38395Q28543151-57F092AD-CDB7-4331-84A6-30312B152244Q30438167-CC26D234-8438-4D1B-95D2-2602EE891814Q33558170-85B07820-C32D-46FD-805D-D39561F78326Q33701577-C086AAD8-FD13-49BC-AD87-E933C9268DFFQ33740176-E359FB12-6301-45C0-A3F2-E3D38A1671B1Q33768466-3CCE32F6-2AEF-4478-ADCC-B6A7129E7F44Q33786824-036E8AF7-292E-4291-8444-C669DAD95CECQ33829022-C697F2A5-EDA5-409F-9670-E8A9B24AF37BQ34023082-F011815D-FE48-4123-84B5-94D004C310E4Q34025065-999B1CBE-F426-4B45-8912-60490993B67CQ34038854-E4EFE9A9-2511-46A4-B794-B86A3E3F42D2Q34049686-B3011097-7EDA-42FF-BA20-5900019AAD76Q34169968-20E6FE4C-05E9-4947-86CC-D8DD3610AEC1Q34174284-E8970971-818F-4161-93CF-F9DCCE924C01Q34418716-E7185A75-D0AD-45C4-ADDF-B80AC0283297Q34418934-129455FE-50B4-4EF5-A58B-AD15F545006CQ34485147-9C513FC7-45AD-409A-974C-B5C567B7D234Q34617837-FCD0B52B-A22A-4F54-9FCA-48BC5479F6A9Q34779509-4BEB237E-3556-4391-9440-5E2DB565970AQ34997270-48710277-B4F5-4075-89D7-7BB86968527BQ35219019-C073BB0E-0042-42DB-82B6-9A3E85A1095BQ35585973-A51AE2F2-D9D6-4771-B23B-4FD5FC084DE3Q35603116-487BCC45-2D7A-45B4-9060-38C0EC6BC39EQ35603128-2BDF37B3-488F-43BE-B380-392811C2992BQ35608638-8C439863-ECB7-4A2F-AF2E-D63394798D93Q35754801-5D7C308F-66D6-4351-8FFD-0AAE2ECC4794Q35868347-7DD2F3F9-DD46-4A00-8795-04FE22116297Q35899430-67E6A113-479A-4917-A519-0FCA06A1AF88Q36289608-0299B82F-36A6-4644-B5D4-B917C0D92453Q36356398-1BA7C850-EA3A-4751-A124-6098C2602E8EQ36561366-6B5A5D7B-5149-4CAB-B5C6-2339BFC90CBFQ36638647-EC965E7E-3497-4D05-908A-09615447AD15Q36732801-78D51AA8-3A21-4A76-B1A2-B151427FC49AQ36733215-D4E3F9FF-7205-4024-AE43-AC5BFD0D7263Q36742501-D5E8B5D2-CC4F-4EF1-8F64-8768743A5063Q36925346-DE9F6C27-2599-437D-BA11-762099AE46FBQ36934224-1EEFBB02-EF78-4D2C-8ED6-9108FE1F5648Q37034189-894B49B1-E366-41AA-8694-C32DC03FC3DC
P2860
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Increasing Wnt signaling in th ...... tumor burden in bone in vivo.
@ast
Increasing Wnt signaling in th ...... tumor burden in bone in vivo.
@en
type
label
Increasing Wnt signaling in th ...... tumor burden in bone in vivo.
@ast
Increasing Wnt signaling in th ...... tumor burden in bone in vivo.
@en
prefLabel
Increasing Wnt signaling in th ...... tumor burden in bone in vivo.
@ast
Increasing Wnt signaling in th ...... tumor burden in bone in vivo.
@en
P2093
P2860
P1433
P1476
Increasing Wnt signaling in th ...... tumor burden in bone in vivo.
@en
P2093
Babatunde O Oyajobi
Barry Grubbs
Brandon McCluskey
Claire M Edwards
Gregory R Mundy
James R Edwards
Javier Esparza
Seint T Lwin
Steven Munoz
P2860
P304
P356
10.1182/BLOOD-2007-03-077685
P407
P577
2007-12-19T00:00:00Z